Skip to content
DataLookout
Menu

WILL-EMI NISNCT06883240

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 23 versions: 17 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words
    • Primary and study completion pushed from Nov 1, 2026 to Jan 18, 2027
    • Study sites: 26 to 25
  2. Minor Study sites: 27 to 26v21
  3. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment increased: 40 → 44 participants
    • Site details revised at 27 of 27 sites
    v20
  4. Minor Site details revised at 2 of 27 sitesv19
  5. Minor Site details revised at 3 of 27 sitesv18
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Site details revised at 1 of 27 sitesv14
  2. Minor Study sites: 26 to 27v13
  3. Minor Study sites: 25 to 26v12
  4. Minor Study sites: 23 to 25v11
  5. Minor Study sites: 20 to 23v9
  6. Minor Study sites: 18 to 20v8
  7. Minor Study sites: 13 to 18v7
  8. Minor Study sites: 8 to 13v6
  9. Minor Start date changed from estimate of May 27, 2025 to Apr 29, 2025v5
  10. Minor Study sites: 4 to 8v4
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 14, 2025 to May 27, 2025
    • Study sites: 0 to 4
    v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualized Bleed Rate (ABR) for Treated Bleeds
Timeframe: From Baseline to at least 24 weeks

Secondary (4)

ABR for All Bleeds
ABR for Treated Spontaneous Bleeds
ABR for Treated Joint Bleeds
Incidence and Severity of Adverse Events, with Severity Determined According to the World Health Organization (WHO) Toxicity Grading Scale

Arms and interventions

Participants with Type 3 VWD Treated with Prophylactic SOC

Participants with Type 3 VWD, aged 2 years and above, who are currently on standard of care (SOC) prophylactic therapy are anticipated to remain on the chosen SOC regimen during the study. Dosing and treatment duration of any studied medicinal products collected as part of this study are at the discretion of the treating physician in accordance with local labeling or local treatment guidelines.

Drugs: Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate

Sites

25 sites in 13 countries

Germany 3, Italy 3, United Kingdom 3, United States 3, Canada 2, France 2, Japan 2, Spain 2, Belgium 1, Colombia 1, Netherlands 1, Poland 1, Sweden 1